Neurotoxicity associated with anesthetics and surgery remains a relevant issue in clinical perioperative care. In the past 15 years, preclinical data in rodents has widely shown that volatile anesthetics induce neuronal apoptosis and impair synaptogenesis in the developing brain, raising suspicion that childhood exposure to anesthetics may confer some degree of permanent cognitive impairment [1] . Confounding variables, including patient comorbidities and the physiologic response to the surgery itself, has complicated a precise determination of the clinical influence of anesthetics on neurodevelopment in children and adolescents, and the topic remains widely debated. Anesthetics have also been implicated in adult postoperative cognitive decline (POCD). The morbidity associated with POCD is large, accounting for increased time to discharge, increased mortality in the first year after surgery, rising public health costs, and susceptibility to delirium and its associated sequelae [2] . POCD is associated with poor compliance with rehabilitation, altered levels of consciousness, and complicates the postoperative administration of opioid analgesics (particularly the use of patient-controlled analgesia). Systematic reviews suggest POCD occurs in >10% of the noncardiac surgery population over 60 years of age [3] . Undoubtedly, how anesthesia and surgery may lead to cognitive impairment in some patients, both young and old, is a complex issue.
In this issue of the Journal of Molecular Medicine, Gui and coauthors shed interesting new light on the role of glial cells in anesthetic neurotoxicity. Glia, including microglia and astrocytes, are nonneuronal cells increasingly recognized for the major roles they play in neuronal development and maintenance in health and disease. Microglia share a common myeloid lineage with monocytes and macrophages, and similarly function in pathogen recognition, phagocytosis (of damaged cells, inactive synapses, debris, and infectious agents), and induction of inflammatory mediators. Astrocytes regulate cerebral circulation, extracellular ionic homeostasis, and release of energy substrates in the brain. In addition to their role in neuronal housekeeping and protection, astrocytes regulate neurotransmission and synapse formation. The neuronal milieu within the brain is supported by the interaction of trophic factors secreted by neurons and glia that mediate synaptic maturation, axonal sprouting during development, and repair following injury. We have previously demonstrated that astrocytes can protect developing neurons from volatile anesthetic neurotoxicity by regulating brain-derived neurotrophic factor, a neurotrophin secreted by neurons [4] . In the present study, Gui et al. further advance the prospect of a central role for astrocytes in protection from anesthetic neurotoxicity by focusing on glial-derived neurotrophic factor (GDNF), a neurotrophin secreted by astrocytes, which plays a critical role in neuronal development and in neuronal protection following injury (Fig. 1) . GDNF is currently being explored as a therapeutic target in a number of nervous system disorders, including Parkinson's disease; however, the role of GDNF in neonatal anesthetic neurotoxicity and the therapeutic potential of GDNF for prevention of adult POCD has not been previously explored.
In their investigations, Gui et al. employed a combined anesthesia-surgery model in neonatal rats, utilizing the most commonly used anesthetic in clinical practice (sevofluorane), and carotid artery exposure for surgical stimulus. They first examined the effects on cognition of combined anesthesia/surgery treatment versus anesthesia alone and observed that while anesthesia alone trended towards impairment in cognition, only the combination of anesthesia plus surgery resulted in significant disruption in learning and memory tasks. This observation suggests that the inflammatory response from surgical tissue injury may play a significant role in neuronal cell death and cognitive impairment. The authors tested this hypothesis by examining postoperative activation of microglia. Under normal physiological conditions, microglia exist in a Bresting^or quiescent state. Brain injury induces microglial activation (Fig. 1) , characterized by a change from a ramified to amoeboid shape, loss of branching processes, and production of lysosomes and phagosomes. They observed a marked upregulation of microglial activation as well as increased release of NF-κB, an important intracerebral transcription factor that activates immune pathways, and an associated decrease in neurogenesis. Notably, they observed reduced expression of GDNF. In other work, an inflammatory response upregulated GDNF expression (indeed, NF-κB mediated the neuroprotective effects of GDNF in other experimental models [5] ), and the authors acknowledge that this may be the first work to demonstrate that neuroinflammation in this context reduces the release of GDNF. It is possible that anesthetics interfere with the inflammation-induced upregulation of GDNF that would otherwise be seen during surgical stress. That is, anesthesia might prevent glial cells from appropriately responding to an inflammatory milieu. Interestingly, in the present study, inactivation of GDNF alone (without surgery) also resulted in learning and memory impairment. Further verifying astrocytes as central for neuroprotection following surgical stress, and as a potential therapeutic target for POCD, the authors demonstrated: (1) inhibition of NF-κB activity with pyrrolidine dithiocarbamate (PDTC) augmented GDNF levels and neurogenesis and (2) either PDTC treatment or intrathecal injection of GDNF reversed the behavioral deficits associated with anesthesia and surgery.
A number of clinical investigations have pointed to attenuation of neuroinflammation as a potential therapeutic approach for POCD. For example, ketamine, a phencyclidine derivative that not only antagonizes glutamate receptors but also has a profound anti-inflammatory effect, attenuates cognitive dysfunction following cardiac surgery [6, 7] . Likewise, parecoxib, a cyclooxygenase-2 inhibitor with marked anti-inflammatory effects, also prevented cognitive decline following orthopedic surgery in an elderly cohort [8] . Recently, it was further described that dexamethasone, well known for reducing neuroinflammation in traumatic brain injury and those with cerebral edema, also improved cognitive outcome following surgery [9] . However, all of these therapies are associated with undesirable side effects, ranging from psychotropic effects, impacts on wound healing and bowel anastomoses, and increased risk of adverse cardiovascular events. Exogenous trophic factor administration might be a Anesthesia and surgery in combination promotes the activation of microglia, which inhibits GDNF release from astrocytes via activation of NF-κB. GDNF antagonism reduces neuronal repair, leading to postoperative cognitive dysfunction and anesthesia/surgery-related neurotoxicity. Anti-inflammatories that antagonize NF-κB, such as PDTC, restore GDNF secretion and improve cognitive outcome. Restoration of cognitive function following anesthesia/surgery can also be achieved by exogenous application of GDNF. GDNF glial-derived neurotrophic factor, NF-κB nuclear factor-kappa B, PDTC pyrrolidine dithiocarbamate gentler therapy for POCD. Indeed GDNF has been demonstrated to have a relatively good safety profile in phase 2 trials for Parkinson's disease [10] . As astrocytes in the human brain are larger, more complex, and greater in number relative to neurons than in the rodent brain, trophic therapies targeting astrocytes may provide a key factor in overcoming translational barriers between rodents and humans. While further preclinical experiments in adult and aged animal models are necessary to determine the clinical potential for GDNF as an effective therapy for POCD, the result from the present study by Gui et al. provides intriguing new data and insight into an increasingly recognized public health problem.
